Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, 117997 Moscow V-437, Russian Federation.
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 8, 630090 Novosibirsk, Russian Federation.
Sci Adv. 2018 Nov 14;4(11):eaau4580. doi: 10.1126/sciadv.aau4580. eCollection 2018 Nov.
We report the development of a novel platform to enhance the efficacy and safety of follicular lymphoma (FL) treatment. Since lymphoma is a clonal malignancy of a diversity system, every tumor has a different antibody on its cell surface. Combinatorial autocrine-based selection is used to rapidly identify specific ligands for these B cell receptors on the surface of FL tumor cells. The selected ligands are used in a chimeric antigen receptor T cell (CAR-T) format for redirection of human cytotoxic T lymphocytes. Essentially, the format is the inverse of the usual CAR-T protocol. Instead of being a guide molecule, the antibody itself is the target. Thus, these studies raise the possibility of personalized treatment of lymphomas using a private antibody binding ligand that can be obtained in a few weeks.
我们报告了一种新平台的开发，以提高滤泡性淋巴瘤 (FL) 治疗的疗效和安全性。由于淋巴瘤是一种多样性系统的克隆恶性肿瘤，每个肿瘤的细胞表面都有不同的抗体。组合的自分泌选择用于快速鉴定 FL 肿瘤细胞表面 B 细胞受体的特定配体。所选配体用于嵌合抗原受体 T 细胞 (CAR-T) 格式，以重新定向人类细胞毒性 T 淋巴细胞。从本质上讲，这种格式与通常的 CAR-T 方案相反。抗体本身不是导向分子，而是目标。因此，这些研究提出了使用可以在几周内获得的私人抗体结合配体对淋巴瘤进行个性化治疗的可能性。
